Financial Performance - The company's revenue for Q1 2025 reached ¥1,093,056,547.55, representing an increase of 11.74% compared to ¥978,184,584.19 in the same period last year[5] - Net profit attributable to shareholders decreased by 4.00% to ¥149,673,716.87 from ¥155,917,808.87 year-on-year[5] - The net profit after deducting non-recurring gains and losses fell by 11.12% to ¥139,838,322.08 compared to ¥157,336,643.80 in the previous year[5] - Total revenue for the current period reached ¥1,093,056,547.55, an increase of 11.7% compared to ¥978,184,584.19 in the previous period[17] - Net profit for the current period was ¥165,298,507.95, slightly higher than ¥164,788,049.79 from the previous period, reflecting a growth of 0.3%[18] Cash Flow and Assets - Operating cash flow increased by 26.98% to ¥224,599,975.82 from ¥176,877,677.26 in the same period last year[5] - The company's total current assets as of March 31, 2025, amounted to RMB 4,898,393,552.36, an increase from RMB 4,789,035,311.56 at the beginning of the period[14] - The company's cash and cash equivalents decreased to RMB 870,405,287.23 from RMB 3,487,699,580.40 at the beginning of the period[14] - The company's trading financial assets increased significantly to RMB 3,123,355,508.41 from RMB 383,928,774.64[14] - The total comprehensive income attributable to minority shareholders was CNY 15,624,791.08, compared to CNY 8,870,240.92 in the previous period, indicating a significant increase[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,981, with the top ten shareholders holding a combined 73.43% of the shares[10] - The company has a significant shareholding structure, with the largest shareholder controlling 55.98% of the total shares[11] - Basic and diluted earnings per share both stood at CNY 0.18, slightly down from CNY 0.19 in the previous period[19] Investment and Expenses - Financial expenses increased by 92.60% to ¥10,902,395.38 due to rising leasing liabilities interest as the company expanded[8] - Other income rose significantly by 177.94% to ¥5,951,452.00, primarily due to increased government subsidies received during the reporting period[9] - Investment income surged by 234.84% to ¥7,508,769.79, attributed to the redemption of financial products during the period[9] - The company reported a decrease in research and development expenses to ¥15,539,755.73 from ¥17,303,375.36, a decline of 10.2%[17] Future Plans and Strategies - The company plans to repurchase shares using its own funds, with a total amount not less than RMB 150 million and not exceeding RMB 250 million, at a price not exceeding RMB 50.93 per share[12] - The company plans to expand its market presence and invest in new technologies to drive future growth[18] - The company is focusing on strategic acquisitions to enhance its competitive position in the market[18] Liabilities and Equity - Total assets at the end of the reporting period were ¥8,079,781,223.49, a 1.97% increase from ¥7,924,043,231.64 at the end of the previous year[5] - Non-current liabilities rose to ¥902,706,135.15, an increase of 3.1% from ¥870,570,443.20 in the last period[16] - The total equity attributable to shareholders reached ¥5,899,996,693.77, up from ¥5,794,409,772.57, indicating a growth of 1.8%[16]
华厦眼科(301267) - 2025 Q1 - 季度财报